...
首页> 外文期刊>Infection and immunity >The Asymptomatic Bacteriuria Escherichia coli Strain 83972 Outcompetes Uropathogenic E. coli Strains in Human Urine
【24h】

The Asymptomatic Bacteriuria Escherichia coli Strain 83972 Outcompetes Uropathogenic E. coli Strains in Human Urine

机译:无症状细菌性大肠杆菌菌株83972在人类尿液中战胜了致病性大肠杆菌菌株

获取原文

摘要

Escherichia coli is the most common organism associated with asymptomatic bacteriuria (ABU). In contrast to uropathogenic E. coli (UPEC), which causes symptomatic urinary tract infections (UTI), very little is known about the mechanisms by which these strains colonize the human urinary tract. The prototype ABU E. coli strain 83972 was originally isolated from a girl who had carried it asymptomatically for 3 years. Deliberate colonization of UTI-susceptible individuals with E. coli 83972 has been used successfully as an alternative approach for the treatment of patients who are refractory to conventional therapy. Colonization with strain 83972 appears to prevent infection with UPEC strains in such patients despite the fact that this strain is unable to express the primary adhesins involved in UTI, viz. P and type 1 fimbriae. Here we investigated the growth characteristics of E. coli 83972 in human urine and show that it can outcompete a representative spectrum of UPEC strains for growth in urine. The unique ability of ABU E. coli 83972 to outcompete UPEC in urine was also demonstrated in a murine model of human UTI, confirming the selective advantage over UPEC in vivo. Comparison of global gene expression profiles of E. coli 83972 grown in lab medium and human urine revealed significant differences in expression levels in the two media; significant down-regulation of genes encoding virulence factors such as hemolysin, lipid A, and capsular polysaccharides was observed in cells grown in urine. Clearly, divergent abilities of ABU E. coli and UPEC to exploit human urine as a niche for persistence and survival suggest that these key differences may be exploited for preventative and/or therapeutic approaches.
机译:大肠杆菌是与无症状菌尿症(ABU)相关的最常见生物。与尿毒症 E相反。导致症状性尿路感染(UTI)的大肠埃希菌(UPEC),对于这些菌株在人尿道中定植的机制知之甚少。原型ABU E。大肠杆菌菌株83972最初是从一个无症状携带3年的女孩中分离出来的。故意将 E感染受UTI感染的个体。大肠杆菌 83972已成功地用作治疗常规疗法难以治疗的患者的替代方法。尽管该菌株不能表达与UTI有关的初级粘附素,但用菌株83972定植似乎可以防止UPEC菌株感染。 P和1型菌毛。在这里,我们研究了 E的生长特性。大肠杆菌 83972在人的尿液中,并显示它在尿液生长方面可以胜过具有代表性的UPEC菌株。 ABU E的独特功能。在人尿路感染的鼠模型中还证实了大肠杆菌83972在尿液中胜过UPEC,从而证实了在体内比UPEC具有选择性优势。 E E的全球基因表达谱比较。在实验室培养基和人尿中生长的大肠杆菌83972显示出两种培养基中表达水平的显着差异。在尿液中生长的细胞中观察到编码毒力因子(如溶血素,脂质A和荚膜多糖)的基因的显着下调。显然,ABU E的能力各不相同。大肠杆菌和UPEC将人类尿液作为持久性和生存性的利基市场表明,这些关键差异可用于预防和/或治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号